This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): elsibucol
Description: AGI-1096 is a selective anti-inflammatory agent that is being developed to address the accelerated inflammation in chronic organ transplant rejection.
Deal Structure: In January 2004, AtheroGenics announced a collaboration with Fujisawa Pharmaceutical Co. (now Astellas Pharma, Inc.), to develop AGI-1096. Under the agreement,Astellas funds all development costs during the term of the agreement and also will receive an option to negotiate for late stage development and commercial rights to the compound.
In February 2006, AtheroGenics announced an extension of its research and development collaboration with Astellas Pharma for AGI-1096.
Under the extension, AtheroGenics and Astellas will continue with additional studies to further explore the therapeutic utility of AGI-1096 in this indication. Astellas will fund all of the development costs during the extended term of the agreement and will retain the exclusive option to negotiate for late stage development and commercial rights to the compound.
Partners: Astellas Pharma, Inc.
Additional information available to subscribers only: